MX373884B - Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta. - Google Patents

Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.

Info

Publication number
MX373884B
MX373884B MX2016004063A MX2016004063A MX373884B MX 373884 B MX373884 B MX 373884B MX 2016004063 A MX2016004063 A MX 2016004063A MX 2016004063 A MX2016004063 A MX 2016004063A MX 373884 B MX373884 B MX 373884B
Authority
MX
Mexico
Prior art keywords
pcv2
pcv2b
infection
subtype
prevention
Prior art date
Application number
MX2016004063A
Other languages
English (en)
Other versions
MX2016004063A (es
Inventor
Christine Margaret Muehlenthaler
Eric Martin Vaughn
Gregory Haiwick
Luis Alejandro Hernández
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of MX2016004063A publication Critical patent/MX2016004063A/es
Publication of MX373884B publication Critical patent/MX373884B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método para la reducción selectiva de un anticuerpo con cisteína diseñada, el método comprende: a) poner en contacto a un agente reductor con moléculas de anticuerpo con cisteína diseñada, cada una de las moléculas de anticuerpo tiene al menos un residuo de cisteína diseñada coronada y al menos un enlace disulfuro intercadena; b) hacer reaccionar el agente reductor con las moléculas de anticuerpo bajo condiciones suficientes para eliminar la corona de los residuos de cisteína diseñada y formar subproductos coronados; y c) eliminar los subproductos coronados durante la reacción de reducción; por lo que se forma una preparación de anticuerpo de cisteína diseñada no coronada y sustancialmente todos los enlaces disulfuro intercadena presentes en las moléculas de anticuerpo antes de la reacción de reducción se retienen en la preparación de anticuerpo de cisteína diseñada no coronada.
MX2016004063A 2013-10-02 2014-10-02 Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta. MX373884B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361885871P 2013-10-02 2013-10-02
PCT/US2014/058793 WO2015051099A1 (en) 2013-10-02 2014-10-02 Pcv2 orf2 protein variant and virus like particles composed thereof

Publications (2)

Publication Number Publication Date
MX2016004063A MX2016004063A (es) 2016-06-06
MX373884B true MX373884B (es) 2020-03-26

Family

ID=51795768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004063A MX373884B (es) 2013-10-02 2014-10-02 Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.

Country Status (12)

Country Link
US (6) US9505808B2 (es)
EP (1) EP3052516B1 (es)
JP (1) JP6778104B2 (es)
KR (2) KR20220083861A (es)
CN (1) CN105658660A (es)
AU (1) AU2014329524B2 (es)
CA (1) CA2924228C (es)
DK (1) DK3052516T3 (es)
EA (1) EA035265B1 (es)
ES (1) ES2778425T3 (es)
MX (1) MX373884B (es)
WO (1) WO2015051099A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
PL2371383T3 (pl) 2005-12-29 2016-01-29 Boehringer Ingelheim Vetmedica Inc Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
US20080226669A1 (en) 2005-12-29 2008-09-18 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
EP2242511A4 (en) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
DK3052516T3 (da) * 2013-10-02 2020-03-23 Boehringer Ingelheim Animal Health Usa Inc PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf
EP3277315A2 (en) * 2015-03-30 2018-02-07 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 carrier platform
EP3294876A1 (en) * 2015-05-14 2018-03-21 Merial, Inc. Method for porcine circovirus production and pcv2 vaccines
CN104984335A (zh) * 2015-07-14 2015-10-21 浙江诺倍威生物技术有限公司 猪圆环病毒双亚型orf2共表达载体构建及疫苗制备
BR112018068078A2 (pt) * 2016-03-07 2019-01-08 Virginia Tech Intellectual Properties Inc vacinas de circovírus suíno tipo 2 (pcv2) quimérico
US10431889B2 (en) * 2016-04-22 2019-10-01 The Charles Stark Draper Laboratory, Inc. Low-loss compact transmit impedance matching tuning technique
CN106399138B (zh) * 2016-09-07 2019-11-12 复旦大学 猪圆环病毒ii型口服病毒样颗粒疫苗及其制备方法和应用
CN106399350B (zh) * 2016-09-07 2020-02-21 复旦大学 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法
EP4570264A3 (en) * 2016-11-03 2026-01-21 Boehringer Ingelheim Vetmedica GmbH Vaccine against porcine parvovirus
CN106834242B (zh) * 2017-03-02 2021-02-23 扬州大学 嵌合型猪圆环病毒活疫苗c1-233株及其构建方法
CN106834241B (zh) * 2017-03-02 2021-01-19 扬州大学 嵌合型猪圆环病毒活疫苗c1-402株及其构建方法
CN107245477B (zh) * 2017-06-06 2020-06-30 广东海大畜牧兽医研究院有限公司 一种猪圆环病毒2型病毒样颗粒的制备方法及通过该方法获得的病毒样颗粒
EP3697804B1 (en) 2017-10-17 2023-08-23 Intervet International B.V. Recombinant expression of pcv2b orf2 protein in insect cells
CN108484725A (zh) * 2018-03-16 2018-09-04 广东海大畜牧兽医研究院有限公司 一种区分检测pcv2野毒抗体与疫苗抗体的多肽及其在elisa检测试剂盒中的应用
CN110358742B (zh) * 2019-07-05 2020-12-22 武汉科前生物股份有限公司 猪圆环病毒2b型和2d型的二价亚单位疫苗及其制备方法
CN111415356B (zh) * 2020-03-17 2020-12-29 推想医疗科技股份有限公司 肺炎征象的分割方法、装置、介质及电子设备
CN112010949B (zh) * 2020-08-03 2021-07-27 山东绿都生物科技有限公司 一种重组pcv2病毒样颗粒蜂胶疫苗及其制备方法
CN114250259B (zh) * 2020-09-21 2024-07-19 成都史纪生物制药有限公司 一种猪圆环2型病毒Cap蛋白病毒样颗粒的发酵培养基
TWI867524B (zh) * 2022-05-09 2024-12-21 福又達生物科技股份有限公司 豬環狀病毒第二型及豬瘟病毒次單位雙價疫苗
CN121463956A (zh) 2023-05-03 2026-02-03 勃林格殷格翰动物保健有限公司 诱导免疫应答的方法
AU2024266173A1 (en) 2023-05-03 2025-12-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for self-administration by pigs
CN118063562B (zh) * 2024-03-11 2025-04-01 天康生物制药有限公司 优化的猪圆环病毒2型Cap蛋白及其病毒样颗粒和应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
US5069901A (en) 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
AU638970B2 (en) 1989-01-23 1993-07-15 Auspharm International Limited Vaccine composition
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5202430A (en) 1990-01-16 1993-04-13 University Of Tennessee Transmissible gastroenteritis virus genes
CA2082155C (en) 1990-05-29 2008-04-15 Krishnaswamy I. Dayalu Swine pneumonia vaccine and method of preparation
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
GB9023111D0 (en) 1990-10-24 1990-12-05 Wellcome Found Expression system
DK0555366T3 (da) 1990-11-01 2000-08-28 Univ Iowa State Res Found Inc Fremgangsmåde til bakteriel svækkelse og vaccine
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
KR0138092B1 (ko) 1991-08-26 1998-04-30 제임스 씨. 데세사레 미확인(Mystery) 돼지 질병 관련 바이러스제
US5580557A (en) 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
DE69518316T2 (de) 1994-05-10 2001-03-29 American Home Products Corp., Madison Modifizierter,verbesserter,lebender brsv impfstoff
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
WO1998006835A2 (en) 1996-08-16 1998-02-19 The Texas A & M University System Modifying insect cell gylcosylation pathways with baculovirus expression vectors
DK0835930T3 (da) 1996-10-09 2001-06-18 Akzo Nobel Nv Europæiske vaccinestammer af porcint reproduktions- og respirationssyndrom-virus. (PRRSV)
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US20060029617A1 (en) 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
NZ505008A (en) 1997-12-11 2003-07-25 Univ Saskatchewan Porcine circovirus (PCV) isolates from pigs displaying postweaning multisystemic wasting syndrome virus
AU770002B2 (en) 1998-03-13 2004-02-12 University Of Georgia Research Foundation, Inc., The Vaccines against circovirus infections
EP0953574A1 (en) 1998-04-30 1999-11-03 Innogenetics N.V. Immunodiagnostic reagent for the detection of Maedi-Visna virus and CAEV infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
EP1050584B1 (en) 1998-11-19 2006-10-18 Azwell Inc. Recombinant lysophosphatidic acid phosphatase
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
WO2001017556A1 (fr) 1999-09-07 2001-03-15 Shionogi & Co., Ltd. Préparations vaccinales administrables par les muqueuses
US6656478B1 (en) 1999-11-12 2003-12-02 Samuel D. Charles Cross-protective salmonella vaccines
EP1248646B1 (en) 1999-12-21 2008-02-13 Merial Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another enteric pathogen
EP1290016A2 (en) 2000-06-15 2003-03-12 Purdue Research Foundation Vaccine for congenital tremors in pigs
US6808900B2 (en) 2000-06-15 2004-10-26 Manitoba, University Of Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
JP2002247979A (ja) 2001-02-23 2002-09-03 Nippon Biologicals Inc マレック病ワクチンおよびその製造方法
KR100876629B1 (ko) 2001-03-27 2009-01-07 유니버시티 오브 사스카췌완 써코바이러스의 배양 방법
US20030096377A1 (en) 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
TNSN03155A1 (fr) 2001-07-02 2005-12-23 Pfizer Prod Inc Vaccination unidose avec mycoplasma hyopneumoniae
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
WO2003068933A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
WO2003077860A2 (en) 2002-03-13 2003-09-25 Biophysica, Inc. BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
US20030215455A1 (en) 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
DK1599164T3 (en) 2003-02-03 2015-04-27 Cerebus Biolog Inc METHODS OF TREATMENT, PREVENTION AND DETECTION OF HELICOBACTER INFECTION
US7563449B2 (en) 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
CN1458167A (zh) 2003-06-02 2003-11-26 中国农业科学院哈尔滨兽医研究所 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
HRP20080235T3 (hr) 2003-07-24 2008-07-31 Merial Limited Formulacija vakcine koja sadrži emulziju ulje-u-vodi
UA87665C2 (ru) 2003-07-25 2009-08-10 Берингер Ингельхайм Ветмедика, Инк. Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis
FR2861731B1 (fr) 2003-10-30 2006-02-24 Centre Nat Rech Scient Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
CN1942204A (zh) 2004-04-26 2007-04-04 株式会社中央疫苗研究所 用于猪呼吸病的灭活混合疫苗及其制备方法
CN1579553A (zh) 2004-05-18 2005-02-16 浙江大学 Ii型猪圆环病毒核酸疫苗的制备方法及其应用
KR20070052273A (ko) 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
AU2011253941B2 (en) * 2004-12-30 2015-01-29 Boehringer Ingelheim Animal Health USA Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
ES2343201T3 (es) 2005-01-13 2010-07-26 Boehringer Ingelheim Vetmedica Gmbh Vacunas contra el srrp.
US7300785B2 (en) 2005-02-03 2007-11-27 Universiteit Ghent Culturing circular ssDNA viruses for the production of vaccines
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
BRPI0607540B1 (pt) 2005-04-13 2017-05-09 Merial Ltd ensaio para a produção de circovírus porcino
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
AU2006289102C1 (en) 2005-09-09 2017-11-30 Intervet International B.V. PCV-2 vaccine
PL2371383T3 (pl) 2005-12-29 2016-01-29 Boehringer Ingelheim Vetmedica Inc Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
US20080226669A1 (en) 2005-12-29 2008-09-18 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
WO2008064299A2 (en) 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
ES2625460T5 (es) 2006-12-15 2020-11-04 Boehringer Ingelheim Animal Health Usa Inc Tratamiento de cerdos seropositivos en anticuerpo anti-PCV2 con antígeno de PCV2
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
GB0712160D0 (en) * 2007-06-22 2007-08-01 Univ Ghent Methods and compositions in the treatment of procine circoviral infection
US20090017064A1 (en) 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
EP2225367A1 (en) 2007-12-21 2010-09-08 Wyeth LLC Methods and compositions for immunizing pigs against porcine circovirus
EP2242511A4 (en) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
US20110033495A1 (en) 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
PT2547770T (pt) 2010-03-16 2020-03-04 Virginia Tech Intellectual Properties Inc Vacina contra circovirus suíno, quimérica, atenuada, viva
WO2011132129A1 (en) 2010-04-22 2011-10-27 Koninklijke Philips Electronics N.V. Skin contact detector
CN103108653B (zh) 2010-07-08 2015-07-22 美国联合生物医学公司 设计肽的pcv2疫苗
WO2012033911A2 (en) 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
EP2564869A1 (en) 2011-09-02 2013-03-06 Ceva Sante Animale Synthetic capsid proteins and uses thereof
CN103122352B (zh) 2012-09-27 2015-02-11 华中农业大学 一种猪圆环病毒2型重组杆状病毒及制备方法和应用
DK2961766T3 (da) 2013-03-01 2019-07-15 Boehringer Ingelheim Animal Health Usa Inc Kvantificering af vaccinesammensætninger
CN105246505A (zh) 2013-04-30 2016-01-13 勃林格殷格翰动物保健公司 PCV2a亚型(PCV2a)的ORF2蛋白用于交叉保护中的用途
DK3052516T3 (da) * 2013-10-02 2020-03-23 Boehringer Ingelheim Animal Health Usa Inc PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf
BR112016023983B1 (pt) 2014-05-07 2022-10-18 Boehringer Ingelheim International Gmbh Contentor para um nebulizador, nebulizador para um fluido e método para conectar um contentor a um dispositivo indicador
EP3277315A2 (en) * 2015-03-30 2018-02-07 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 carrier platform

Also Published As

Publication number Publication date
MX2016004063A (es) 2016-06-06
DK3052516T3 (da) 2020-03-23
EA035265B1 (ru) 2020-05-21
KR20160058958A (ko) 2016-05-25
US20250243246A1 (en) 2025-07-31
EP3052516B1 (en) 2020-01-01
AU2014329524A1 (en) 2016-03-17
KR102409183B1 (ko) 2022-06-15
US20150093404A1 (en) 2015-04-02
US10961281B2 (en) 2021-03-30
US12247051B2 (en) 2025-03-11
US20170029471A1 (en) 2017-02-02
CA2924228A1 (en) 2015-04-09
ES2778425T3 (es) 2020-08-10
WO2015051099A1 (en) 2015-04-09
CN105658660A (zh) 2016-06-08
US20240076321A1 (en) 2024-03-07
EP3052516A1 (en) 2016-08-10
JP6778104B2 (ja) 2020-10-28
JP2016534034A (ja) 2016-11-04
CA2924228C (en) 2024-01-16
EA201600305A1 (ru) 2016-09-30
US11858963B2 (en) 2024-01-02
US10131696B2 (en) 2018-11-20
KR20220083861A (ko) 2022-06-20
US9505808B2 (en) 2016-11-29
AU2014329524B2 (en) 2019-01-17
US20190023747A1 (en) 2019-01-24
US20210221852A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
MX373884B (es) Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
EA201790630A1 (ru) Способы получения рибозидов
EA201590890A1 (ru) Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу
EP2985288A4 (en) PIGS PSEUDORABIESVIRUS, VACCINE COMPOSITION, AND METHOD OF PREPARATION AND USE THEREOF
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
PH12017500450A1 (en) Flavivirus virus like particle
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
WO2016100615A3 (en) Methods and composition for neutralization of influenza
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
WO2014140166A3 (en) Vaccine
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
MX2014014521A (es) Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
MX350283B (es) Virus recombinantes de influenza porcina y usos del mismo.
PH12014501688A1 (en) Influenza c virus and vaccine
EA201390452A1 (ru) Вакцина
MX2015011064A (es) Vacuna contra el virus de la leucemia bovina.
MX2013009310A (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

FG Grant or registration